Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843634 · ClinicalTrials.gov registry record · Early Phase 1
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
A Early Phase 1 study of Acute Myeloid Leukemia, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01843634 is a Early Phase 1 study of Acute Myeloid Leukemia that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 10 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01843634, a Early Phase 1 study of Acute Myeloid Leukemia, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label pilot study evaluating the safety and preliminary evidence of a therapeutic effect of ODSH (2-0, 3-0 desulfated heparin) in conjunction with standard induction and consolidation therapy for acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG ODSH
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01843634
The ClinicalTrials.gov registry entry for NCT01843634 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (91% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which ODSH is the first listed.
NCT01843634 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT01843634 about?
NCT01843634 is a clinical study titled "Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia". This is an open-label pilot study evaluating the safety and preliminary evidence of a therapeutic effect of ODSH (2-0, 3-0 desulfated heparin) in conjunction with standard induction and consolidation therapy for acute myeloid leukemia.
What is the current status of trial NCT01843634?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2013-08. Estimated completion is 2015-04.
What conditions does trial NCT01843634 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT01843634?
The interventions under investigation include: ODSH (DRUG).
Who is sponsoring clinical trial NCT01843634?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01843634 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RECRUITING · Early Phase 1
-
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
RECRUITING · Early Phase 1
-
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
RECRUITING · Early Phase 1
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
COMPLETED · Early Phase 1
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.